Efficacy and Safety of Initial Combination Therapy in Treatment-Na⟨ve Type 2 Diabetes Patients: A Systematic Review and Meta-analysis

被引：35
作者：
Cai, Xiaoling [1 ]
Gao, Xueying [1 ]
Yang, Wenjia [1 ]
Han, Xueyao [1 ]
Ji, Linong [1 ]
机构：
[1] Peking Univ, Peoples Hosp, Dept Endocrine & Metab, Beijing, Peoples R China
来源：
DIABETES THERAPY | 2018年 / 9卷 / 05期
基金：
国家重点研发计划;
关键词：
DPP-4; inhibitors; Drug-naive; HbA1c; Hypoglycemia; Initial combination; FIXED-DOSE COMBINATION; IMPROVES GLYCEMIC CONTROL; DIPEPTIDYL PEPTIDASE-4 INHIBITORS; ALOGLIPTIN PLUS METFORMIN; DRUG-NAIVE PATIENTS; DOUBLE-BLIND; COMPONENT MONOTHERAPY; CHINESE PATIENTS; ASIAN PATIENTS; GLUCOSE-LEVELS;
D O I：
10.1007/s13300-018-0493-2
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Introduction: The aim of this study was to evaluate the efficacy and safety of initial combination therapy compared with monotherapy in drug-nai ve type 2 diabetes patients. Methods: MEDLINE, Embase and the Cochrane Central Register of Controlled Trials were searched for randomized clinical trials of initial combination therapy with hypoglycemic agents compared with monotherapy. Those which satisfied the search criteria were included in the meta-analysis. Weighted mean difference and relative risks were calculated. Results: A total of 36 studies were included in the meta-analysis. Compared with metformin monotherapy, initial combination therapy with metformin plus another anti-diabetes drug exhibited significant reductions in glycated hemoglobin (HbA1c) (p\ 0.001). Most of the combination therapies had a similar risk of hypoglycemia (p[ 0.05), with the exception of combinations of sulfonylurea/ glinide and metformin or combinations of thiazolidinedione and metformin. Compared with dipeptidyl peptidase-4 (DPP-4) inhibitor monotherapy, initial combination therapy with DPP-4 inhibitor plus another anti-diabetes drug showed a significant decrease in HbA1c (p\ 0.001) and a similar risk of hypoglycemia (p[ 0.05). Compared with monotherapy with other anti-diabetes drugs, initial combination therapies also resulted in significant HbA1c reductions, a similar risk of hypoglycemia and similar risks of other adverse events. Conclusion: Compared with monotherapy, all initial combination therapies resulted in significant HbA1c reductions. Compared with metformin monotherapy, initial combination therapies with DPP-4 inhibitors plus metformin, sodium/ glucose cotransporter 2 inhibitors and metformin, respectively, were associated with similar risks of hypoglycemia, but initial combination therapies with sulfonylurea plus metformin, thiazolidinedione and metformin, respectively, were associated with higher risks of hypoglycemia.
引用
收藏
页码：1995 / 2014
页数：20
相关论文
共 60 条
[1]   Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial [J].
Abdul-Ghani, M. A. ;
Puckett, C. ;
Triplitt, C. ;
Maggs, D. ;
Adams, J. ;
Cersosimo, E. ;
DeFronzo, R. A. .
DIABETES OBESITY & METABOLISM, 2015, 17 (03) :268-275
[2]   Combination of Saxagliptin and Metformin Is Effective as Initial Therapy in New-Onset Type 2 Diabetes Mellitus With Severe Hyperglycemia [J].
Amblee, Ambika ;
Lious, Daniel ;
Fogelfeld, Leon .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2016, 101 (06) :2528-2535
[3]  
American Diabetes Association, 2017, Diabetes Care, V40, pS64
[4]   A randomized, parallel group, double-blind, multicentre study comparing the efficacy and safety of Avandamet (rosiglitazone/metformin) and metformin on long-term glycaemic control and bone mineral density after 80 weeks of treatment in drug-naive type 2 diabetes mellitus patients [J].
Borges, J. L. C. ;
Bilezikian, J. P. ;
Jones-Leone, A. R. ;
Acusta, A. P. ;
Ambery, P. D. ;
Nino, A. J. ;
Grosse, M. ;
Fitzpatrick, L. A. ;
Cobitz, A. R. .
DIABETES OBESITY & METABOLISM, 2011, 13 (11) :1036-1046
[5]   Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus [J].
Bosi, E. ;
Dotta, F. ;
Jia, Y. ;
Goodman, M. .
DIABETES OBESITY & METABOLISM, 2009, 11 (05) :506-515
[6]   Clinical Considerations for Use of Initial Combination Therapy in Type 2 Diabetes [J].
Cahn, Avivit ;
Cefalu, William T. .
DIABETES CARE, 2016, 39 :S137-S145
[7]   Introduction [J].
Cheng, Alice Y. Y. .
CANADIAN JOURNAL OF DIABETES, 2013, 37 :S1-S3
[8]   Initial treatment with fixed-dose combination rosiglitazone/glimepiride in patients with previously untreated type 2 diabetes [J].
Chou, H. S. ;
Palmer, J. P. ;
Jones, A. R. ;
Waterhouse, B. ;
Ferreira-Cornwell, C. ;
Krebs, J. ;
Goldstein, B. J. .
DIABETES OBESITY & METABOLISM, 2008, 10 (08) :626-637
[9]   Meta-analysis of binary outcomes from two-by-two tables when the length of follow-up varies and hazards are proportional [J].
Combescure, C. ;
Courvoisier, D. S. ;
Haller, G. ;
Perneger, T. V. .
STATISTICAL METHODS IN MEDICAL RESEARCH, 2011, 20 (05) :531-540
[10]   From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus [J].
DeFronzo, Ralph A. .
DIABETES, 2009, 58 (04) :773-795
123456